Tango Therapeutics (TNGX) Operating Leases (2020 - 2026)

Tango Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 12.21% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $30.0 million, a 12.21% decrease from a year earlier, with the FY2025 full-year figure at $30.8 million, down 9.42% from the prior year.
• Operating Leases retreated to $30.0 million in Q1 2026 per TNGX's latest filing, from $30.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $39.9 million in Q3 2022 and bottomed at $30.0 million in Q1 2026.
• The 5-year median for Operating Leases is $35.5 million (2024), against an average of $35.3 million.
• Across the five-year window, Operating Leases soared 556.05% in 2022 and declined 12.21% in 2026, its largest moves.
• Year by year, Operating Leases stood at $39.4 million in 2022, then dropped by 6.41% to $36.8 million in 2023, then dropped by 7.6% to $34.0 million in 2024, then slipped by 9.42% to $30.8 million in 2025, then slipped by 2.84% to $30.0 million in 2026.
• Per Business Quant, the three latest TNGX Operating Leases figures stand at $30.0 million (Q1 2026), $30.8 million (Q4 2025), and $31.7 million (Q3 2025).